LISTING OF THE CLAIMS

Please cancel without prejudice or disclaimer claims 1, 2 and 10-19, please amend claims 3, 4, 8, 9, 24 and 25 and please add claims 26-30. The following listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Canceled)

2. (Canceled)

3. (Currently Amended) A method of providing analgesia to a subject in need thereof comprising administering a pharmaceutical composition comprising enantiomerically pure L-methadone or a mixture of DL methadone having at least 65% L-methadone and ~~at least one additional opioid analgesic~~ morphine, wherein the pharmaceutical composition is administered in an amount and a duration sufficient to potentiate an antinociceptive response.

4. (Currently Amended) A method of providing analgesia to a subject in need thereof comprising administering a pharmaceutical composition comprising enantiomerically pure L-methadone or a mixture of DL methadone having at least 65% L-methadone and administering a pharmaceutical composition comprising and ~~at least one additional opioid analgesic~~ morphine, wherein the pharmaceutical compositions are administered in an amount and a duration sufficient to potentiate an antinociceptive response.

5. (Previously Presented) The method according to claim 4, wherein enantiomerically pure L-methadone or the mixture of DL methadone having at least 65% L-methadone is administered in a dosage range from about 1 mg to about 60 mg.

6. (Previously Presented) The method according to claim 4, wherein enantiomerically pure L-methadone or the mixture of DL methadone having at least 65% L-methadone is administered in a dosage range from about 2 mg to about 10 mg.

7. (Canceled)

8. (Currently Amended) The method according to claim [[7]] 4, wherein morphine is administered in a dosage range from about 0.1 mg to about 60 mg.

9. (Currently Amended) The method according to claim [[7]] 4, wherein morphine is administered in a dosage range from about 1 mg to about 50 mg.

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Previously Presented) The method according to claim 3, wherein the pharmaceutical composition comprises a mixture of DL methadone having at least 65% L-methadone.

21. (Previously Presented) The method according to claim 4, wherein the pharmaceutical composition comprising L-methadone is a mixture of DL methadone having at least 65% L-methadone.

22. (Previously Presented) The method according to claim 3, wherein the pharmaceutical

composition comprises a mixture of DL methadone and the antinociceptive response is therapeutic for moderate or severe pain.

23. (Previously Presented) The method according to claim 4, wherein the pharmaceutical composition comprising L-methadone is a mixture of DL methadone and the antinociceptive response is therapeutic for moderate or severe pain.

24. (Currently Amended) A method for potentiating an antinociceptive response by providing analgesia from enantiomerically pure L-methadone or a mixture of DL methadone having at least 65% L-methadone and ~~at least one additional opioid analgesic~~ morphine in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising L-methadone and ~~at least one additional opioid analgesic~~ morphine in an amount and a duration sufficient to potentiate an antinociceptive response.

25. (Currently Amended) A method for potentiating an antinociceptive response by providing analgesia from enantiomerically pure L-methadone or a mixture of DL methadone having at least 65% L-methadone and ~~at least one additional opioid analgesic~~ morphine in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising L-methadone and administering a pharmaceutical composition comprising at least one additional opioid analgesic, both in an amount and a duration sufficient to potentiate an antinociceptive response.

26. (New) A method of providing analgesia to a subject in need thereof comprising administering a pharmaceutical composition comprising L-methadone and at least one additional opioid analgesic selected from the group consisting of , morphine-6- glucuronide, 6-acetylmorphine, and codeine, wherein the pharmaceutical composition is administered in an amount and a duration sufficient to potentiate an antinociceptive response.

27. (New) The method according to claim 26, wherein the comprising L-methadone comprises a racemic mixture of DL methadone having at least 65% L-methadone.

28. (New) The method according to claim 26, wherein the pharmaceutical composition comprising L-methadone comprises a mixture of DL methadone and the antinociceptive response is

therapeutic for moderate or severe pain.

29. (New) A method for potentiating an antinociceptive response by providing analgesia from L-methadone and at least one additional opioid analgesic selected from the group consisting of , morphine-6- glucuronide, 6-acetylmorphine, and codeine, in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising L-methadone and administering a pharmaceutical composition comprising at least one additional opioid analgesic, both in an amount and a duration sufficient to potentiate an antinociceptive response.

30. (New) A method for potentiating an antinociceptive response by providing analgesia from L-methadone and at least one additional opioid analgesic selected from the group consisting of , morphine-6- glucuronide, 6-acetylmorphine, and codeine, in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising L-methadone and administering a pharmaceutical composition comprising at least one additional opioid analgesic, both in an amount and a duration sufficient to potentiate an antinociceptive response.